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Abstract
Introduction. Medicinal product Noclaud®, containing cilostazol, was approved in Poland on 19.03.2014 
without performing a study on its effectiveness in polish population. 
The aim of this study was to evaluate the efficacy of Noclaud® in the therapy of intermittent claudication (the 
second stage according to Fontaine classification) in patients with peripheral artery disease (PAD), in whom 
lifestyle modifications and supervised exercise programs did not alleviate the symptoms.
Material and methods. Non-interventional, multi-center, open, post-registration observational study on 
Noclaud® effectiveness was conducted on 1680 patients with PAD (second stage according to the Fontaine). 
The assessment of Noclaud® effectiveness included changes in the initial and total claudication distances and 
changes in ankle-brachial index (ABI). Adverse effects were recorded.
Results. Administration of Noclaud® resulted in an increase in the initial claudication distance by 88 (95% 
CI: 76–100) and 125 (106–145) m after 3 and 6 months, respectively, and the total claudication distance 
by 121 (99–142) and 148 (119–177) m after 3 and 6 months, respectively. Also during the six minute walk 
test, distances increased by 64 (57–72) and 104 (93–114) m after 3 and 6 months, respectively.
ABI increased by 0.04 (0.03–0.05), and the percentage of patients with ABI < 0.9 decreased significantly 
(from 90.3 to 72.5%; p < 0.001). However, the percentage of patients with ABI < 0.4 did not change (1.2 
vs. 0.9%).
Conclusions. Medicinal product Noclaud® increases claudication distance in patients with second grade 
peripheral artery disease, according to the Fontaine classification. The administration of this drug has only 
minor effects on the ankle-brachial index.
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Introduction
Noclaud® (active substance — cilostazol) is a se-
lective phosphodiesterase inhibitor type 3 (PDE3) that 
increases the production of cyclic adenosine monophos-
phate (cAMP). The increase in cAMP concentration 
results in enhanced synthesis of the active protein kinase 
A (PKA), which is directly associated with inhibition of 
platelet aggregation. PKA also prevents activation of 
the myosin light chain kinase, which plays an important 
role in smooth muscle contraction and thus exerts 
a vasodilating effect [1].
The effects of cilostazol on blood vessel dilation 
reported in animal studies were also established in 
humans. Furthermore, in vitro studies revealed that ci-
lostazol inhibits proliferation of smooth muscle vascular 
cells in rats and humans, as well as inhibiting excretion 
of platelet derived growth factor (PDGF) and platelet 
factor 4 (PF-4) from thrombocytes. Inhibition of platelet 
aggregation by cilostazol is reversible and effective with 
respect to a number of pro-aggregation factors such 
as shear stress, arachidonic acid, collagen, adenosine 
diphosphate (ADP), and adrenaline [1, 2]. In human 
studies, it was observed that the anti-aggregation effect 
of cilostazol is maintained for 12 hours. After discon-
tinuation, platelet aggregation returns to normal within 
48–96 hours without excessive rebound aggregation 
[3, 4]. It has also been found that after 12 weeks the use 
of cilostazol at the dose of 100 mg twice a day reduced 
serum triglyceride levels by 15% and increased HDL 
serum levels by 10% [5].
Results of a meta-analysis of 10 randomized studies, 
which included 2247 patients, showed that the use of 
cilostazol improved exercise capacity, as measured 
by the change in total claudication distance and the 
initial claudication distance (to the onset of pain), 
in comparison to placebo [6]. In addition, results of 
a meta-analysis conducted on 9 studies revealed that 
administration of cilostazol at the dose of 100 mg twice 
a day significantly increased the maximum walking 
distance by 42 meters during 24 weeks of treatment 
compared to placebo. The observed improvement was 
less pronounced in diabetic patients [7]. The results of 
a randomized, double-blinded, placebo-controlled, 
phase IV study conducted on 1435 patients with in-
termittent claudication without heart failure showed 
that during the 18-month (median) follow-up period, 
mortality rate during the administration of cilostazol 
accounted to 5.6% (95% CI: 2.8–8.4%), whereas in 
placebo reached 6.8% (95% CI 1.9–11.5%) [8].
The aim of this study was to evaluate the efficacy 
of Noclaud® in the therapy of intermittent claudication 
(the second stage according to Fontaine classification) in 
patients with peripheral artery disease (PAD), in whom 
lifestyle modifications and supervised exercise programs 
did not alleviate the symptoms.
Material and methods
This was an open, non-interventional multi-center 
post-registration study collecting data on the effec-
tiveness and adverse effects of the medicinal product 
Noclaud®, administered for 6 months according to the 
recommendations specified in the Summary of Product 
Characteristics in adults (above 18 years old) with inter-
mittent claudication without pain at rest or peripheral 
necrosis (grade 2 according to the Fontaine classifica-
tion), in whom advised changes in lifestyle (including 
quitting smoking and supervised exercise program) 
and other appropriate interventions did not sufficiently 
reduce the symptoms of intermittent claudication. The 
inclusion criterion included administration of Noclaud® 
for at least 14 days, but no longer than 3 months. The 
exclusion criteria were as given in the Summary of 
Product Characteristics [4]. Participation in the study 
did not result in any further diagnostic procedures or 
additional surveillance. According to the Polish law, 
a non-interventional post-registration study is not 
classified as a medical experiment therefore does not 
require consent of a bioethics committee and informed, 
written consent for participation in the study.
One-hundred-ten vascular surgeons, angiologists 
and primary care physicians participated in the study, 
performing 7–9 months follow-up in 1680 patients 
receiving Noclaud® as routine treatment. Specified 
period for evaluation of the effectiveness of this drug, 
including the period of treatment before the first visit.
Follow-up sheet
The follow-up sheet consisted of three sections that 
were to be completed during three separate follow-up 
visits.
During visit 1, demographic and anthropometric 
data were collected, as well as data regarding current 
pharmacotherapy for lower limb ischemia, the time and 
dose of Noclaud® administered, initial and total walking 
distance, ABI before administration of Noclaud®, med-
ical history regarding concomitant diseases and current 
medications, and reported adverse effects related to 
administration of Noclaud®.
153www.journals.viamedica.pl/acta_angiologica
Jerzy Chudek, Efficacy of Noclaud® in the therapy of intermittent claudication
Table 1. Characteristics of the study group (n = 1680)
Sex (M/W) (%) 69.1/30.9
Age [years ± SD] 65.1 ± 21.1
BMI [kg/m2] 27.8 ± 3.7
25.0–29.9 kg/m2 (%) 55.8
≥ 30.0 kg/m2 (%) 24.8
Severity of peripheral artery disease 
according to Fontaine classification (%)
Grade 2a 42.2
Grade 2b 52.7
Grade 2c 5.1
Modification of lifestyle before  
administration of Noclaud® (%)
Walking 53.6
Quitting smoking 44.1
Other (diet, physical exercise,  
physical therapy, bike riding)
2.3
Pharmacotherapy for peripheral  
artery disease prior to administration 
of Noclaud® (%)
56.3
Pentoxifylline (% of treated patients) 82.9
Naftidrofuryl (% of treated patients) 4.9
Sulodexide (% of treated patients) 1.5
Bencyklan (% of treated patients) 1.6
Acenocoumarol (% of treated patients) 0.2
Acetylsalicylic acid (% of treated patients) 7.8
Ticlopidine (% of treated patients) 0.2
Other (% of treated patients) 0.9
Other preparations for treatment  
of peripheral artery disease (%)
48.0
Acetylsalicylic acid 39.1
Ticlopidine (% of other) 32.4
Clopidogrel (% of other) 1.9
Acenocoumarol (% of other) 0.4
Bencyclan (% of other) 3.4
Pentoxifylline (% of other) 7.2
L-arginine (% of other) 0.4
PP vitamin (% of other) 0.2
Heparin (% of other) 0.2
Sulodexide (% of other) 0.9
Statins (% of other) 9.3
Fibrats (% of other) 0.7 
Concomitant diseases (%) 82.6
Hypertension 33.5
Lipid disorders 21.5
Coronary disease 12.1
A history of myocardial infarction 2.6
Past stroke 1.9
Heart failure 1.3
Arrhythmias 2.3
Chronic kidney disease 1.2
Type 2 diabetes 11.8
Type 1 diabetes 0.7
Obesity 6.4
BMI — body mass index
During visits 2 and 3, which took place at approx-
imately 3-monthly intervals, data regarding the effec-
tiveness of the treatment administered (initial and total 
walking distance, ABI) were collected along with data 
regarding changes in pharmacotherapy for concomi-
tant diseases, and reported adverse effects related to 
administration of Noclaud®.
Data analysis
The effectiveness of Noclaud® administration was 
assessed based on an increases in initial (without pain) 
and total claudication distance on the treadmill, and in 
the maximal walking distance in 6-minut walking test 
and increase in ankle-brachial index (ABI) in comparison 
with the index estimated before treatment.
ABI below 0.9 was classified as indicating ischemia 
and below 0.4 as critical ischemia.
Statistical analysis
Statistical analysis was performed using STATISTICA 
10.0 PL software. The qualitative data was presented as 
percentages, whereas quantitative data was presented 
as means with standard deviations and confidence inter-
vals. Distribution of qualitative variables was compared 
using the c2 test and c2 for the trend. Whereas, the 
ANOVA test was used to compare variances in quan-
titative variables, p < 0.05 was considered statistically 
significant.
Results
Characteristics of the study group
The study included 1680 patients, with a mean age of 
65 ± 21 years and 69.1% of patients were men. 42.2% 
of patients included were classified as having stage 2a 
(according to Fontaine classification) claudication, 52.7% 
had stage 2b and 5.1% had stage 2c (Table 1).
Before the administration of Noclaud®, a treadmill 
test was performed in 25.1% of the patients, and 
a six-minute walk test in 41.2% of patients. In addition 
ABI was measured in 54.5% of patients and critical is-
chemia was detected in 1.2% of the tested population 
(Table 2).
Lifestyle modifications were implemented before 
the administration of Noclaud® in 90.8% of patients. 
These included smoking cessation (44.1%) and increas-
ing physical activity by walking (53.6%). Only 6.5% 
of patients participated in the supervised exercise 
programs.
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Table 2. Changes in blood pressure, heart rate, claudication distance and ankle-brachial index and administration of statins,  
fibrates and antiplatelet drugs during the use of Noclaud®
Visit I 
(n = 1680)
Visit II 
(n = 1609)
Visit III 
(n = 1554)
ANOVA/c2
Systolic blood pressure [mm Hg] 139 ± 14 137 ± 12 135 ± 11 p < 0.001
≥ 140 mm Hg (%) 65.5 46.5 37.8 p < 0.001
Diastolic blood pressure [mm Hg] 83 ± 10 81 ± 8 80 ± 8 p < 0.001
≥ 90 mm Hg (%) 33.7 24.2 20.1 p < 0.001
Heart rate [1/min] 76 ± 8 75 ± 7 75 ± 7 NS
ECG performance (%) 48.0 27.5 25.3
NS
Normal ECG (%) 84.2 90.1 91.6
Treadmill test performed (%) 25.1* 21.0 20.6
Initial claudication distance [m] 208 ± 145 288 ± 188 332 ± 221 p < 0.001
≥ 200 m (%) 49.3 67.9 77.5
50–200 m (%) 45.2 30.0 22.2 p < 0.001
< 50 m (%) 5.5 2.2 0.35
Total claudication distance [m] 399 ± 357 468 ± 350 524 ± 393 p < 0.001
≥ 200 m (%) 73.9 87.4 91.2
50–200 m (%) 24.6 11.9 8.8 p < 0.001
< 50 m (%) 1.5 0.7 0
6-minut walk test performed (%) 41.2* 37.6 36.7
Walking distance [m] 249 ± 155 310 ± 169 351 ± 190 p < 0.001
≥ 200 m (%) 59.4 74.7 85.2
50–200 m (%) 38.8 24.5 14.4 p < 0.001
< 50 m (%) 1.8 0.8 0.4
ABI measured (%) 54.5* 57.8 56.7
ABI value 0.77 ± 0.16 0.81 ± 0.16 0.85 ± 0.16 p < 0.001
0.4 ≤ ABI ≤ 0.9 [1/1] 89.1 81.5 71.6 p < 0.001
ABI < 0.4 [1/1] 1.2 1.0 0.9 NS
Statins (%) 91.1 90.9 90.9 NS
Fibrates (%) 8.3 8.5 8.5 NS
Acetylsalicylic acid (%) 18.8 26.0 25.2 p < 0.01
Clopidogrel/ticlopidin (%) 16.5 0.6 0.6 p < 0.001
*Before initiation therapy with Noclaud®
Prior Noclaud® administration 56.3% of patients 
were receiving pharmacotherapy for PAD, mostly 
included pentoxifylline (82.9%), acetylsalicylic acid 
(7.8%) and naftidrofuryl (4.9%) — see Table 1. Statins 
were prescribed in 91.1% of subjects, often due to 
concomitant diseased.
Treatment for hypertension, lipid disorders and 
diabetes was carried out in 71.0%, 67.8% and 24.5% 
of patients respectively.
Treatment with the Noclaud® preparation
Noclaud® was prescribed at the recommended dose 
of 2 × 100 mg in 98.6% of patients. At the first visit 
the drug was used for 25 ± 11 days at mean. During 
follow-up visits, doses were not modified.
During treatment with Noclaud® a mild decrease 
in diastolic and systolic blood pressure from 139 ± 14 
to 135 ± 11 mm Hg (p < 0.001) and from 83 ± 10 to 
80 ± 9 (p < 0.001) was observed. The heart rate did 
not change (Table 2). No increase in the percentage of 
abnormal ECG records was observed.
Effectiveness of the treatment  
with Noclaud® preparation
Administration of Noclaud® resulted in an increase 
in initial claudication distance on the treadmill by 
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Table 3. Increase in the claudication distance during the study. Data shown as mean values and 95% CI
2 vs. 1 3 vs. 1 p
Increase in the initial claudication distance [m ] 88 (76–100) 125 (106–145) < 0.001
Increase in the total claudication distance [m] 121 (99–142) 148 (119–177) < 0.001
Increase in the distance during 6-minute walk test [m] 64 (57–72) 104 (93–114) < 0.001
Figure 3. The increase in ankle-brachial index (ABI) during 
therapy with Noclaud® after and 6 months (visit 3)
Figure 1A. Increases in the initial claudication distance on the treadmill during therapy with Noclaud® after 3 (visit 2) and 6 (visit 3) 
months; B. Increases in the total claudication distance on the treadmill during therapy with Noclaud® after 3 (visit 2) and 6 (visit 3) 
months
A B
Figure 2. Increases in distances in 6-minute walk test during 
therapy with Noclaud® after 3 (visit 2) and 6 (visit 3) months
88 (95% CI: 76–100) m after 3 months, and 125 (106– 
–145) m after 6 months, and the total claudication dis-
tance increased by 121 (99–142) m after 3 months and 
148 (119–177) m after 6 months (Figure 1). Also dur-
ing the six-minute walk test the distance increased by 
64 (57–72) m after 3 months and by 104 (93–114) m 
after 6 months (Table 3, Figures 1 and 2).
ABI increased from 0.81 (0.80–0.82) to 0.85 (0.84–
–0.87) — p < 0.001 (analysis of the subgroups in which 
the initial and final test was performed) — the average in-
crease in ABI was 0.04 (95% CI: 0.03–0.05) — Figure 3. 
The percentage of patients with ABI < 0.9 decreased 
significantly from 90.3 to 72.5% (p < 0.001). How- 
ever, the percentage of patients with ABI < 0.4 did not 
change significantly (1.2 vs. 0.9%) — Table 2.
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Causes of treatment discontinuation
There were 126 patients (7.5%) who did not 
complete the observation. One patient died (no data 
concerning the cause is available). Eighty patients 
discontinued treatment, but only in four it was due to 
adverse drug reactions (0.24% of the study cohort). 
The most common reason of discontinuation was lack 
of money to buy the drug (25 patients, 1.5% of the 
population). One patient discontinued the treatment 
after revascularization. In addition, 45 patients were 
lost to follow-up.
Adverse drug reactions
Adverse effects related to administration of Noclaud® 
were reported in 5 patients and included: arrhythmias 
(n = 4), headaches and dizziness (n = 1), and malaise 
(n = 1) — the severity of symptoms were not specified.
Discussion
The results of this study, as well as previous clinical 
studies performed in patients with symptomatic chronic 
lower limb ischemia, show that treatment with cilosta-
zol is effective and results in increased claudication 
distance. Results of a meta-analysis of seven randomized 
clinical trials (2008) with placebo groups showed that 
administration of cilostazol at a dose of 100 mg twice 
a day increased claudication distance by 31 (95% CI: 
21–41) and by 41 (27–90) m respectively, at a dose of 
50 mg twice a day for 12 to 24 weeks [9]. In this study, 
not controlled against placebo, the observed increase 
in the initial claudication distance related to the admin-
istration of Noclaud® was by 88 (95% CI: 76–100) m 
after 3 months, and 125 (106–145) m after 6 months 
on treadmill testing, and the total claudication distance 
by 121 (95% CI: 99–142) after 3 months and 148 (119– 
–177) m after 6 months during a six-minute walk test. 
The observed differences between this study and the 
average results of seven randomized clinical trials may 
result from differences in the study cohorts analyzed in 
terms of symptom severity, concomitant heart diseases 
(e.g. ischemic heart disease), lung diseases (e.g. COPD), 
and musculoskeletal disorders. 
A few studies have examined the effect of cilostazol 
on ABI. Mohler at al. reported an increase in ABI by 
0.03–0.04 after 24 weeks of treatment with the initial 
ABI values of 0.62–0.63 [10]. Dawson et al. reported 
a similar increase in ABI by 0.04 after 24 weeks of treat-
ment with cilostazol in 227 patients with intermittent 
claudication [11]. Slightly higher increase in ABI among 
patients treated with cilostazol (by 0.06–0.07) was 
observed by Elam at al. [5] and Money et al. [12]. The 
increase in ABI at rest during administration of Noclaud® 
was similar to the one observed in previously performed 
research and accounted for 0.04 (95% CI: 0.03–0.05).
It should be emphasized that treatment with No-
claud® was generally safe and well tolerated by patients. 
Adverse drug reactions were reported by only 5 pa-
tients (0.3% of the treated population). These included 
arrhythmias, pain, vertigo, and malaise. No diarrhea or 
other disturbances in defecation, which were reported 
in previous studies on the original product [4], were 
reported in this study.
The limitation of this multicenter study is the lack of 
standardization of measurement protocol of the initial 
and total claudication distances. 
Conclusions
1. Noclaud® increases the claudication distance in 
patients with peripheral artery disease grade 
2 according to Fontaine classification. 
2. The administration of this drug has only minor ef-
fects on the ankle-brachial index.
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